LYLudmila Yasko

Ludmila Yasko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ludmila Yasko has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hematological malignancies in constitutional mismatch repair deficiency syndrome

    by Yu. A. Tikhonova, V. V. Klyukhin, D. A. Evstratov, M. A. Klimentova, L. A. Yasko, N. V. Myakova, M. A. Kurnikova, Ю. А. Тихонова, В. В. Клюхин, Д. А. Евстратов, et al.

    Introduction . Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare childhood cancer predisposition syndrome. Aim : to present a unique clinical case of a patient with relapsed T-lymphoblastic lymphoma who was diagnosed with a rare hereditary cancer predisposition syndrome (constitutional mismatch repair deficiency syndrome). Main findings. The cause of CMMRD is considered to be the presence of biallelic germline homo- or compound-heterozygous variants in one of the four MMR genes ( MLH1, MSH2, MSH6 or PMS2 ); inactivation of these genes leads to an increased mutational burden and, consequently, to malignant transformation of cells. Loss of MMR system function underlies the development of a broad spectrum of malignancies in children and adolescents, with the first neoplasm often presenting as a hematological malignancy. The long-term prognosis for patients with CMMRD remains extremely poor due to the high risk of developing metachronous malignancies of other localizations, which necessitates systematic surveillance of this patient group.

  • Open Access

    Tumor predisposition syndromes in patients with SHH group medulloblastoma

    by Marina M. Koldasheva, L. I. Papusha, E. A. Salnikova, A. E. Druy, M. A. Kurnikova, G. A. Novichkova, N. S. Grachev, L. A. Yasko

    Introduction. Medulloblastomas (MB) of the SHH group account for 25–30% of all MBs and are associated with aberrant activation of the intracellular SHH signaling pathway. The incidence of tumor predisposition syndromes (TPS) in patients with MB of the SHH group is about 20%, and this is the highest rate among the other molecular genetic subgroups of MB. In addition, there is significant molecular genetic heterogeneity within the same group, which in turn contributes to variations in survival rates and prognosis. Objective – to analyze the clinical, molecular, and genetic characteristics of TPS in patients with SHH group MB. Materials and methods. This retrospective study included a cohort of 40 patients aged 0 to 18 years with SHH group MB who underwent molecular genetic diagnostic testing between 2018 and 2024 at the D. Rogachev National Medical Research Center. The MB group was determined using NanoString technology. To identify germline mutations, DNA isolated from peripheral blood was examined using the following methods: next-generation sequencing, whole genome sequencing, Sanger sequencing, multiplex ligation-dependent probe amplification. The amplification of the MYC and NMYC genes was detected using fluorescence in situ hybridization. This study did not require approval from the local Ethics Committee, as the analyzed data did not contain any personalized information. Consent was obtained for the peripheral blood testing for TPS and for the publication of the data. Statistical processing and analysis of the data obtained were carried out using the R package version 4.4.2. Overall survival was estimated using the Kaplan–Meier method, and the cumulative incidence of secondary tumors was estimated using the competing risk method. To calculate the overall survival, we used the time from the date of diagnosis to death, and for the cumulative incidence of secondary tumors, we used the time from the date of diagnosis to the development of a secondary tumor, while death was considered a competing event. Results. Fifteen out of 40 patients were diagnosed with TPS. Gorlin syndrome was diagnosed in 7 people, Li–Fraumeni syndrome in 4 patients, there was one case each of Lynch syndrome and neurofibromatosis type 1, and a mutation in the ELP1 gene. One child had a combination of two syndromes (Gorlin and Lynch). The incidence of TPS in the analyzed cohort of 40 people was 37.5%. Thirteen people are alive, 2 patients died. The overall 4-year survival rate was 93% (the 95% confidence interval 82–100). A secondary tumor developed in 4 patients. The 4-year cumulative incidence of secondary tumors was 31% (the 95% confidence interval 6.4–61.0). All patients who developed a secondary tumor had received radiation therapy. Conclusion. When detecting MB of the SHH, it is important to conduct molecular genetic testing for TPS, given their high frequency among patients with MB of this molecular subgroup. The data obtained will help optimize therapy (avoid radiation therapy for young children with confirmed Gorlin syndrome), as well as predict the course of the disease. In addition, genetic testing is necessary for follow-up of such patients and for counseling their parents regarding the familial forms of the described syndromes.

  • Open Access

    A familial case of DICER1 syndrome in a patient with pleuropulmonary blastoma

    by M. V. Teleshova, L. A. Yasko, E. V. Maslenkova, N. N. Merkulov, D. M. Konovalov, M. A. Kurnikova, I. V. Doronina, T. V. Shamanskaya, D. Yu. Kachanov

    Pleuropulmonary blastoma (PPB) is a very rare tumor of childhood that arises from the mesenchyme of the lung and is associated with mutations in the DICER1 gene. The present article describes a familial case of DICER1 syndrome in a patient aged 3 years and 11 months who underwent investigations and treatment for type II/III PPB of the lower lobe of the left lung at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications. The diagnosis was made based on the results of the pathology investigation of the tissue obtained by open biopsy. Furthermore, the diagnosis was confirmed by the review of histological specimens in the International PPB Registry (Minneapolis, USA). According to the data from the chest CT with intravenous contrast enhancement, the tumor was described as a mass consisting of cystic cavities of various calibers accumulating a contrast agent along the periphery, and a solid component. Specific combination treatment was based on the recommendations of the International PPB Registry and included chemotherapy according to the IVADo/IVA regimen and surgical treatment as a local control. Currently, specific treatment has been completed, the patient is alive with no signs of the disease, the follow-up period was 20 months. As regards the patient's family history, he has a sibling (older brother) who was diagnosed with a cystic nephroma at the age of 1 year and 4 months. Molecular genetic testing of the tumor tissues obtained from the patient (PPB) and his sibling (cystic nephroma) revealed pathogenic somatic variants in the DICER1 gene. Along with the somatic genetic variants, another pathogenic variant was found in both children, the germline status of which was confirmed. The germline variant in the DICER1 gene was inherited from the mother. Thus, the investigations confirmed a familial case of DICER1 syndrome. The case described in this article indicates that families in which DICER1 syndrome was found require special management aimed at early detection of tumors and non-tumor conditions associated with this syndrome in the carriers of pathogenic alleles.

  • Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis

    by Margarita Zaytseva, Andge Valiakhmetova, Ludmila Yasko, Alexey Samarin, Ludmila Papusha, Anastasia Shekhtman, Natalia Usman, Kirill Voronin, Alexander Karachunskiy, Galina Novichkova, et al.

    Choroid plexus carcinomas (CPCs) are rare aggressive pediatric tumors of the brain with no treatment standards. Genetic profiling of CPCs is often confined to possible association with Li–Fraumeni syndrome, though only about a half of CPCs develop from syndromic predispositions. Whole-chromosome gains and losses typical of CPCs reflect genomic instability of these tumors, but only partially explain the aggressive clinical course. This retrospective study enrolled 25 pediatric patients with CPC, receiving treatment between January 2009 and June 2022. Molecular genetic testing was performed for 20 cases with available tumor tissue and encompassed mutational status, chromosomal aberrations and gene expression profiles. We analyzed several factors presumably influencing the outcomes, including molecular profiles and clinical parameters. The median follow-up constituted 5.2 years (absolute range 2.8–12.6 years). All studied CPCs had smooth mutational profiles with the only recurrent event being TP53 variants, either germline or somatic, encountered in 13 cases. Unbalanced whole-chromosome aberrations, notably multiple monosomies, were highly typical. In seven tumors, chromosome losses were combined with complex genomic rearrangements: segmental gains and losses or signs of chromothripsis. This phenomenon was associated with extremely low 5-year survival: 20.0±17.9% vs. 85.7±13.2%; p=0.009. Transcriptomically, the cohort split into two polar clusters Ped_CPC1 and Ped_CPC2 differing by survival: 31.3±17.8% vs. 100%; p=0.012. CPCs split into at least two molecular subtypes distinguished both genomically and transcriptomically. Clusterization of the tumors into Ped_CPC1 and Ped_CPC2 significantly correlates with survival. The distinction may prove relevant in clinical trials for dedicated and patient-oriented optimization of clinical protocols for these rare tumors.


  • Open Access

    Germinal and somatic genetic variants of NF1 in neuroblastoma: own experience and literature review

    by N. A. Andreeva, T. V. Shamanskaya, D. Yu. Kachanov, L. A. Yasko, M. A. Kurnikova, R. Kh. Abasov, A. E. Druy

    Introduction. Neuroblastoma (NB) is the most common embryonic extracranial malignant neoplasm in children. The contribution of the NF1 gene to the development of NB is discussed in the literature, but there is no evidence of the pathogenetic role of NF1 gene aberrations in NB. According to various literature sources, the occurrence of pathogenic variants in the NF1 gene in the general cohort of patients with NB does not exceed 1–6 %.Materials and methods. The molecular genetic examination by next generation sequencing (NGS) was performed in 77 patients with NB during the period from April 2019 to July 2021 in the Laboratory of Molecular Oncology Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology. The staging of patients was carried out within the framework of the international staging system, stratification into risk groups and therapy according to the protocol of the German Group for the study of NB GPOH NB-2004. International criteria of the response assessment system for patients with NB were used to assess the response to treatment. Calculations of event-free and overall survival by the Kaplan–Mayer method for the follow-up period up to 12.01.2022 were performed.Results and discussion. The cohort of patients included in the study was represented by patients with an initially unfavorable prognosis. Patients were divided into 3 groups: without pathogenic variants in genes belonging to the RAS-RAF-MEK pathway and TP53 – “RAS-/ TP53-” (n = 43), with clinically significant variants in the NF1 gene – “NF1+” (n = 12), clinically significant variants in the genes of RAS-RAF-MEK and TP53 pathway – “RAS+/TP53+” except NF1 (n = 22). The median age for the entire group of patients at the time of diagnosis was 41 months (0.1–173 months). Boys prevailed over girls with a ratio of 1.5:1. Patients with stage 4 of the disease according to the INSS classification prevailed – 81.8 % (63/77), high-risk groups according to the NB-2004 protocol – 77.9 % (60/77).In our study 13 clinically significant variants in NF1 were identified in 12 patients (15.6 %), of which 4 were germinal, 9 were somatic. The frequency of detection of pathogenic aberrations in the NF1 gene was much higher than the literature data, which can be associated with a selective cohort of studied patients with an unfavorable prognosis and patients with suspected hereditary genetic syndrome. The presentation of adverse events was observed in 83.3 % of patients, more often against the background of specific therapy (in 60 % of cases), which may be due to the rapid acquisition of NB chemoresistance, among other things. When comparing the three groups, it was shown that the frequency of objective responses to induction therapy was statistically significantly lower in the group of patients “NF1+”, when compared with other groups (p = 0.015; p = 0.024), which may also indicate the chemoresistance of NF1-aberrated NB. When analyzing survival there was no statistical difference between the compared groups.Conclusions. The data obtained by us do not allow us to consider the presence of genetic variants in NF1 separately as a prognostic factor, however, it can be assumed that a group of patients with an unfavorable prognosis may be enriched with cases with mutations in the NF1 gene. Refractory course of the disease/development of adverse events in the presence of genetic variants of NF1, causing the activation of the RASRAF- MEK signaling pathway, leads to the induction of tumor chemoresistance. The presence of clinical significance of aberrations in the NF1 gene does not lead to a statistically significant difference in prognosis when compared with patients with aberrations in other components of the RAS-RAF-MEK pathway, however, longer catamnestic follow-up of patients is necessary.Currently, there are no effective drugs for the treatment of NF1-associated NB in clinical practice that requires further study of the mechanisms of chemoresistance development in such patients. Understanding the molecular and genetic features of the course of NF1-associated NB can become the basis for the development of personalized therapy in the future.

  • Open Access

    SMARCA4-associated malignant rhabdoid tumors: case report and literature review

    by N. A. Andreeva, E. I. Lyudovskikh, D. M. Konovalov, M. V. Teleshova, A. M. Mitrofanova, M. A. Kurnikova, L. A. Yasko, A. E. Druy, M. Yu. Goroshkova, T. V. Shamanskaya, et al.

    Malignant rhabdoid tumor (MRT) is a rare malignant neoplasm of childhood, characterized by an aggressive course and an extremely unfavorable prognosis. The frequency of MRT outside the central nervous system (extracranial MRT) is 0.02–0.03 per 100,000 children. In most cases, MRT is based on an inactivating mutations of the tumor suppressor gene SMARCB1, which leads to the absence of expression of the SMARCB1 ((INI1/hSNF5/BAF47) protein in tumor cells. Aberrations of the SMARCA4 gene, which is an extremely rare molecular event, have been described among the MRTs expressing SMARCB1 (INI1). Few case reports have been described in the international literature.This article contains a description of a clinical case of a patient diagnosed with soft tissue MRT with SMARCA4 gene alteration. The distinctive features of the presented case are the congenital nature of the tumor, atypical localization, and extremely aggressive clinical course of the disease. On the example of the described clinical case, diagnostics of SMARCA4-associated MRT are presented, as well as the place of molecular methods in diagnosis verification. In addition, it is highlighted that the detection of somatic changes in the SMARCB1 and SMARCA4 genes requires additional investigation of their germinal status to exclude or confirm the rhabdoid tumor predisposition syndrome.


  • Long‐term survival of a patient with metastatiс choroid plexus carcinoma, de novo germline TP53 mutated, after craniospinal proton irradiation

    by Andge Valiakhmetova, Ludmila Yasko, Ludmila Papusha, Margarita Zaytseva, Alexander Druy, Ludmila Shishkina, Galina Novichkova, Sergey Gorelyshev, Alexander Karachunsky


  • Open Access

    Pediatric cystic nephroma: clinical and molecular genetic characteristics

    by M. V. Teleshova, L. A. Yasko, E. V. Maslеnkova, N. N. Merkulov, A. M. Mitrofanova, M. A. Kurnikova, E. E. Manzhurtseva, D. G. Akhaladze, G. V. Tereshchenko, N. G. Perevozchikova, et al.

    Cystic nephroma (CN) is a rare renal tumor occurring in children which belongs to a group of neoplasms linked with the inherited DICER1 syndrome. Given the rarity of CNs, it is important to describe clinical, radiological, and molecular genetic characteristics of these tumors in children and adolescents as well as to analyze treatment outcomes. We present our experience in managing 8 patients with histologically verified CN who received treatment and consultations at the D. Rogachev NMRCPHOI over a period of 9 years (2012–2020). The study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI. The patients’ parents gave their consent to the use of their child’s data, including photographs, for research purposes and in publications. We performed a retrospective analysis of clinical presentation, radiological findings, the extent of treatment given to patients, treatment outcomes, and the results of molecular genetic testing. The study included patients aged between 8.6 and 197 months at diagnosis (the median age was 14.2 months). The analysis of initial complaints revealed that six patients (75%) had an increased abdominal girth and a palpable mass in the abdomen, one patient (12.5%) presented with arterial hypertension, and another patient (12.5%) had a mass detected by a routine abdominal ultrasound examination. On contrast-enhanced computed tomography scans, CNs appeared as multicystic masses with thin, contrast-enhancing septa; the CN volume ranged from 59.7 to 1293.1 cm3 (the median volume was 626.3 cm3 ). In all cases, the diagnosis of CN was verified histologically. Surgical treatment included nephrectomy (n = 6) or partial resection of the affected kidney (n = 2) with the removal of the tumor. Some patients (n = 5) included in our analysis received pre-operative chemotherapy at the discretion of their treating physicians. Molecular genetic testing was carried out for 7 children: 4 out of 7 patients (57.1%) were found to have somatic and germline mutations in the DICER1 gene. Carriers of pathogenic DICER1 variant were identified in the family of 1 patient. The median duration of follow-up was 17.6 months (range: 1.7 to 58.9 months). Currently, all patients are alive, no relapses have occurred. Cystic renal neoplasms detected by radiological investigations should be reviewed at the reference centers for pediatric oncological diseases and included CN in the differential diagnosis. Initial surgery is the first line of treatment for cystic nephroma. The final diagnosis is made on the basis of a histological examination of tumor tissue. All patients with confirmed CN should be referred for genetic counseling and molecular genetic testing for germline mutations in the DICER1 gene and should receive surveillance recommendations for the early detection of other metachronous DICER1-associated tumors.

  • Open Access

    DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR IN CHILDREN: MR CHARACTERISTICS, CLINICAL FEATURES AND OUTCOME. FOUR CLINICAL CASES

    by A. F. Valiakhmetova, L. I. Papusha, A. V. Artemov, G. V. Tereshchenko, E. A. Sal’nIkova, L. A. Yasko, A. Е. Druy, A. Р. Shekhtman, G. A. Novichkova, A. I. Karachunsky, et al.

    Background. Diffuse leptomeningeal glioneuronal tumor (DLGNT) is an extremely rare entity first officially recognized in 2016 WHO classification of tumors of the central nervous system. Magnetic resonance imaging (MRI) of this tumor usually visualizes diffuse meningeal infiltration with contrast enhancement, with the presence of multiple small contrast‑negative cysts, visible mainly in the T2 images. The main molecular markers of DLGNTs include the KIAA1549-BRAF fusion gene, BRAF V600E substitution is less common.The aim of this work is to describe the manifestation of DLGNT, its neuroimaging and molecular genetic characteristics, the experience of using anti‑BRAF and anti‑MEK therapy.Materials and methods. In this article are described four cases of DLGNT. The first patient with the presence of the KIAA1549-BRAF fusion in the tumor tissue received a full course of SIOP‑LGG / 2004 chemotherapy (carbo‑ platin and vincristine), the stabilization of the disease on the MRI remains for 4 years after completion of treatment. Second patient with KIAA1549-BRAF fusion gene in tumour tissue received MEK inhibitor trametinib as first line of treatment with the stabilization of the disease on control MRI which last for 2 years. A third patient with a mutation in the BRAF V600E gene. After disease progression on standard chemotherapy (carboplatin and vincristine) according to the SIOP‑LGG / 2004 protocol, anti‑BRAF therapy with vemurafenib was prescribed. After 10 months on MRI a complete response was recorded, which persists during the drug intake for 2.5 years. In the fourth patient, no molecular genetic aberrations were detected; a refractory / progressive course of the dis‑ ease was noted. To date, the stabilization of the disease is recorded on the fourth line of chemotherapy (everoli‑ mus and temozolomide).Conclusion. Given the rarity of this tumor and the lack of consensus about therapy, despite the limited number of observations, our experience allows us to recommend molecular testing of DLGNT to detect activating events in the BRAF gene, as well as consideration of anti‑BRAF / MEK therapy if either the BRAF V600E mutation is de‑ tected or KIAA1549-BRAF fusion.


  • Open Access

    The first experience of using MEK inhibitors for type 1 neurofibromatosis in children in the Russian Federation in a hospital for short-term treatment at the National Medical Research Center

    by N. M. Ershov, A. V. Pshonkin, Yu. M. Mareeva, L. A. Yasko, M. V. Kurnikova, D. A. Evstratov, D. A. Gobadze, L. A. Papusha, G. S. Ovsyannikova, A. G. Rumyantsev

    Neurofibromatosis is a genetic disorder that affects the bones, soft tissues, skin, and the nervous system. Neurofibromatosis has been described in 1882, however, there is still no specific treatment for this disease and no treatment protocols for the most frequent and life-threatening complications such as non-malignant tumors deriving from the cells of the peripheral nerve sheaths. Progress in molecular genetic study discovered the underlying genetic alteration in this tumor. This knowledge provides the base for clinical trials with new drugs. MEK-inhibitors are acting on the RAS-MAPK signaling pathway and have shown their efficacy in decreasing the size of inoperable tumors in children with type 1 neurofibromatosis (NF1). Although, this therapy does not completely reduce the tumor volume, it can significantly improve the quality of life. This article presents a clinical case of the trametinib efficacy in a child suffering from NF1-associated plexiform neurofibromas.